HIKMA PHARMACEUTICALS USA INC. - NEW AWARD FOR HYDRALAZINE HCL INJECTIONS WITH HIKMA PHARMACEUTICALS USA, INC. ORDERING PERIOD IS 1/20/2026 - 1/19/2027 WITH FOUR ONE-YEAR OPTIONS.
Key Details
Description
NEW AWARD FOR HYDRALAZINE HCL INJECTIONS WITH HIKMA PHARMACEUTICALS USA, INC. ORDERING PERIOD IS 1/20/2026 - 1/19/2027 WITH FOUR ONE-YEAR OPTIONS.
Context & Analysis
On Feb 25, 2026, Department of Veterans Affairs to HIKMA PHARMACEUTICALS USA INC. for new award for hydralazine hcl injections with hikma pharmaceuticals usa, inc. ordering period is 1/20/2026 - 1/19/2027 with four one-year options.. The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition after exclusion of sources with 2 offers received. The procurement used a NO SET ASIDE USED. set-aside. This award is one of several similar procurements from Department of Veterans Affairs under NAICS 325412 — related awards are listed below.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.